GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells via MRGPRX2 and MRGPRB2
G protein-coupled receptor (GPCR) kinase 2 (GRK2), which phosphorylates agonist-occupied GPCRs to promote their desensitization, has been investigated as an attractive therapeutic target for cardiovascular and metabolic diseases. Several GRK2-targeted inhibition strategies have been reported includi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1032497/full |
| _version_ | 1811229284479533056 |
|---|---|
| author | Monica Thapaliya Aetas Amponnawarat Aetas Amponnawarat John J. G. Tesmer Hydar Ali |
| author_facet | Monica Thapaliya Aetas Amponnawarat Aetas Amponnawarat John J. G. Tesmer Hydar Ali |
| author_sort | Monica Thapaliya |
| collection | DOAJ |
| description | G protein-coupled receptor (GPCR) kinase 2 (GRK2), which phosphorylates agonist-occupied GPCRs to promote their desensitization, has been investigated as an attractive therapeutic target for cardiovascular and metabolic diseases. Several GRK2-targeted inhibition strategies have been reported including the use of direct pharmacological inhibitors such as paroxetine (a widely prescribed antidepressant) and its analogs such as compound CCG258747. Cross-linking of high affinity IgE receptor (FcϵRI) on mast cells (MCs) and the resulting degranulation causes anaphylaxis and allergic asthma. Using gene silencing strategy, we recently showed that GRK2 contributes to FcεRI signaling and MC degranulation. The purpose of this study was to determine if the GRK2 inhibitors paroxetine and CCG258747 modulate FcεRI-mediated MC responses in vitro and in vivo. Utilizing rat basophilic leukemia (RBL-2H3) cells and primary mouse lung MCs (LMCs), we found that paroxetine and CCG258747 inhibit FcϵRI-mediated calcium mobilization and degranulation. Furthermore, intravenous administration of paroxetine and CCG258747 in mice resulted in substantial reduction of IgE-mediated passive cutaneous anaphylaxis. Unlike LMCs, human cutaneous MCs abundantly express a novel GPCR known as MRGPRX2 (mouse; MRGPRB2). We found that in contrast to their inhibitory effects on FcεRI-mediated MC responses, both paroxetine and CCG258747 induce calcium mobilization and degranulation in RBL-2H3 cells stably expressing MRGPRX2 but not in untransfected cells. Furthermore, paroxetine and CCG258747 induced degranulation in peritoneal MCs from Wild-type (WT) mice in vitro and caused increased cutaneous vascular permeability in vivo, but these responses were substantially reduced in Mrgprb2−/− mice. Additionally, upon intradermal injection, paroxetine also induced neutrophil recruitment in WT but not Mrgprb2−/− mice. These findings suggest that in addition to their potential therapeutic utility against cardiovascular and metabolic disorders, paroxetine-based GRK2-inhibitors may serve to modulate IgE-mediated anaphylaxis and to enhance cutaneous host defense by harnessing MC’s immunomodulatory property through the activation of MRGPRX2/MRGPRB2. |
| first_indexed | 2024-04-12T10:11:57Z |
| format | Article |
| id | doaj.art-26fc1329f9ae43bcada9a57b6be7c3cc |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T10:11:57Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-26fc1329f9ae43bcada9a57b6be7c3cc2022-12-22T03:37:17ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-10-011310.3389/fimmu.2022.10324971032497GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells via MRGPRX2 and MRGPRB2Monica Thapaliya0Aetas Amponnawarat1Aetas Amponnawarat2John J. G. Tesmer3Hydar Ali4Department of Basic and Translational Sciences, University of Pennsylvania, School of Dental Medicine, Philadelphia, PA, United StatesDepartment of Basic and Translational Sciences, University of Pennsylvania, School of Dental Medicine, Philadelphia, PA, United StatesDepartment of Family and Community Dentistry, Faculty of Dentistry, Chiang Mai University, Chiang Mai, ThailandDepartments of Biological Sciences and of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, United StatesDepartment of Basic and Translational Sciences, University of Pennsylvania, School of Dental Medicine, Philadelphia, PA, United StatesG protein-coupled receptor (GPCR) kinase 2 (GRK2), which phosphorylates agonist-occupied GPCRs to promote their desensitization, has been investigated as an attractive therapeutic target for cardiovascular and metabolic diseases. Several GRK2-targeted inhibition strategies have been reported including the use of direct pharmacological inhibitors such as paroxetine (a widely prescribed antidepressant) and its analogs such as compound CCG258747. Cross-linking of high affinity IgE receptor (FcϵRI) on mast cells (MCs) and the resulting degranulation causes anaphylaxis and allergic asthma. Using gene silencing strategy, we recently showed that GRK2 contributes to FcεRI signaling and MC degranulation. The purpose of this study was to determine if the GRK2 inhibitors paroxetine and CCG258747 modulate FcεRI-mediated MC responses in vitro and in vivo. Utilizing rat basophilic leukemia (RBL-2H3) cells and primary mouse lung MCs (LMCs), we found that paroxetine and CCG258747 inhibit FcϵRI-mediated calcium mobilization and degranulation. Furthermore, intravenous administration of paroxetine and CCG258747 in mice resulted in substantial reduction of IgE-mediated passive cutaneous anaphylaxis. Unlike LMCs, human cutaneous MCs abundantly express a novel GPCR known as MRGPRX2 (mouse; MRGPRB2). We found that in contrast to their inhibitory effects on FcεRI-mediated MC responses, both paroxetine and CCG258747 induce calcium mobilization and degranulation in RBL-2H3 cells stably expressing MRGPRX2 but not in untransfected cells. Furthermore, paroxetine and CCG258747 induced degranulation in peritoneal MCs from Wild-type (WT) mice in vitro and caused increased cutaneous vascular permeability in vivo, but these responses were substantially reduced in Mrgprb2−/− mice. Additionally, upon intradermal injection, paroxetine also induced neutrophil recruitment in WT but not Mrgprb2−/− mice. These findings suggest that in addition to their potential therapeutic utility against cardiovascular and metabolic disorders, paroxetine-based GRK2-inhibitors may serve to modulate IgE-mediated anaphylaxis and to enhance cutaneous host defense by harnessing MC’s immunomodulatory property through the activation of MRGPRX2/MRGPRB2.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1032497/fullGRK2paroxetinemast cellsMRGPRX2FcϵRIanaphylaxis |
| spellingShingle | Monica Thapaliya Aetas Amponnawarat Aetas Amponnawarat John J. G. Tesmer Hydar Ali GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells via MRGPRX2 and MRGPRB2 Frontiers in Immunology GRK2 paroxetine mast cells MRGPRX2 FcϵRI anaphylaxis |
| title | GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells via MRGPRX2 and MRGPRB2 |
| title_full | GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells via MRGPRX2 and MRGPRB2 |
| title_fullStr | GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells via MRGPRX2 and MRGPRB2 |
| title_full_unstemmed | GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells via MRGPRX2 and MRGPRB2 |
| title_short | GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells via MRGPRX2 and MRGPRB2 |
| title_sort | grk2 inhibitors paroxetine and ccg258747 attenuate ige mediated anaphylaxis but activate mast cells via mrgprx2 and mrgprb2 |
| topic | GRK2 paroxetine mast cells MRGPRX2 FcϵRI anaphylaxis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1032497/full |
| work_keys_str_mv | AT monicathapaliya grk2inhibitorsparoxetineandccg258747attenuateigemediatedanaphylaxisbutactivatemastcellsviamrgprx2andmrgprb2 AT aetasamponnawarat grk2inhibitorsparoxetineandccg258747attenuateigemediatedanaphylaxisbutactivatemastcellsviamrgprx2andmrgprb2 AT aetasamponnawarat grk2inhibitorsparoxetineandccg258747attenuateigemediatedanaphylaxisbutactivatemastcellsviamrgprx2andmrgprb2 AT johnjgtesmer grk2inhibitorsparoxetineandccg258747attenuateigemediatedanaphylaxisbutactivatemastcellsviamrgprx2andmrgprb2 AT hydarali grk2inhibitorsparoxetineandccg258747attenuateigemediatedanaphylaxisbutactivatemastcellsviamrgprx2andmrgprb2 |